GRANTS & Funding 

This page contains links to information on TRI grant schemes and previous grant recipients. You can also click here to view links and ideas for external funding sources and bodies.

TRI Foundation 2022 research grants

In 2022, the TRI Foundation is pleased to offer two grant schemes in breast cancer and kidney disease research. Both grant schemes are for early to mid-career TRI-based researchers and affiliated clinicians.  Applications are now open for both until 5th September 2022. READ MORE 

Linc Grant Scheme 2022 

TRI, Metro South Health, Mater and Children's Health Queensland (Oncology Department) have joined together to offer the annual LINC grants, worth up to $50,000 each. These grants are aimed at fostering new collaborative research projects between TRI-based researchers and Mater, Metro South Health, Mater or Children's Health Queensland clinicians. FIND OUT MORE 

TRI-CSIRO Grant Scheme 2022 

TRI and the CSIRO Australian e-Health Research Centre are offering three $100,000 grants for collaborative research projects aimed at solving a healthcare challenge. All grant applications must involve a TRI-based researcher, CSIRO Australian e-Health Research Centre scientist and a TRI partner clinician (from either Metro South Health, Mater or Children's Health Queensland).  FIND OUT MORE

TRI Research funding support - Requesting a Letter of support from TRI for Funding 

TRI Funding Support and Letters of Support can be applied for using the "TRI Funding Support - Application for Research Funding" form or by contacitng [email protected]
Applications need to be made three weeks prior to the submission deadline for the relevant grant applications, and must include: 
   
  1. What is novel about the proposal and what is its value-add as a TRI investment for the TRI community.
  2. Previous funding requests to TRI (successful or not) to the same or a different funding body.
  3. How the application meets each of the criteria against which it will be assessed by TRI.
  4. Support from the Institute Director at TRI of the primary applicant (CIA).
Please note: Only one application as the Principal Investigator will be considered for TRI Funding Support in a calendar year. It is possible to be included on multiple applications if a Co-investigator. 
 
 

past FUNDING PROGRAMS AT TRI

Prior to the LINC program, TRI ran the Spore and Drive grant schemes for translational research projects based at the Institute. The aim was to support researchers progress their discoveries and translate their findings into the clinic. Through Spore and Drive, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745. 

 

TRI GRANT RECIPIENTS

Year awarded

Grant scheme

Principal Investigator

Project title

2015

Spore

Dr Michelle Hill

Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools

2015

Spore

Dr Antje Blumenthal

Towards biomarkers for patient stratification in sepsis

2015

Spore

Prof Rik Thompson

Portable, single-sided MRI for routine, low-cost analysis of mammographic density

2015

Spore

Prof Ken O'Byrne

Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability

2016

Spore

A/Prof Jyotsna Batra

Novel MicroRNA’s as potential targets for treating prostate cancer

2016

Spore

A/Prof Chamindie Punyadeera

Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy

2018

Spore

Prof Gerald Holtmann

Modulation of the GI Microbiome with probiotics to treat constipation

2018

Spore

Prof John Hooper

Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer

2018

Spore

Dr Arutha Kulasinghe

Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer?

2018

Spore

Prof Peter Soyer

Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies

2019

Spore

A/Prof Jyotsna Batra

Improving the PSA test to detect all lethal prostate cancers

2019

Spore

Prof Ben Panizza

Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC)

2019

Drive

Prof Sandro Porceddu

Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer

2021

LINC

Dr Justine Gibson
Dr Giorgia Mori

Dysbiosis as a long-term sequelae in patients that undergo treatment for tuberculosis

2021

LINC

Dr Sidharth Mantha
Dr Thomas Kryza

Establishing a pipeline for rapid clinical translation of novel biomaterials for the treatment of brain cancer of metastatic origin

2021

LINC

A/Prof Erin McMeniman
Dr Snehlata Kumari

Determining Causative Mechanisms of Hidradenitis Suppurativa

2021

LINC

Dr Philip Rowell
Dr Lisa Philp

Elucidating the Role of Adipokine Axis Dysregulation in Bone Metastatic Cancer for the Strategic Positioning of New Therapeutic Agents

2021

LINC

Dr Timothy Edwards
Dr Yuanhao Yang

Making treatment-resistant schizophrenia more treatable: predicting life-threatening clozapine-induced-neutropenia using cellular genomics.

2021

LINC

Dr Yoon-Kyo An
Dr Kavita Bisht

Identifying mechanism and new therapies to treat anaemia of inflammation in Inflammatory Bowel Diseases

2021

LINC

Dr Reuben Beer
Dr Marcus Gray

Linking Advanced Neuroimaging, Disease State and Clinical Measures in Multiple Sclerosis: A multi-disciplinary and multi-institutional research approach.

2021

LINC

Dr Jesrine Hong
Dr Sandra Richardson

DNA methylation in circulating free fetal DNA: A potential biomarker to predict fetal growth restriction and severe perinatal outcomes?